Publications by authors named "L Hoegl"

Background And Objectives: In vitro and in vivo experimental data for fozivudine tidoxil [BM21.1290 (FZD) an ether-lipid conjugate of zidovudine] have shown better efficacy, no myelotoxicity and better tolerability compared with zidovudine. Therefore, the objectives of our study were to evaluate the safety of FZD in patients with human immunodeficiency virus (HIV) infection and to establish basic pharmacokinetic data.

View Article and Find Full Text PDF

The family of aspartic proteases such as cathepsin D, gastricin, pepsin, renin, HIV protease and others have been the subject of molecular modeling in the field of drug design in the last years. The first aspartic protease inhibitor was reported thirty years ago as a renin inhibitor. The success of HIV protease inhibitors in preventing progression to AIDS was based on the transition state analogs of renin inhibitors.

View Article and Find Full Text PDF

A 38-year-old woman infected with human immunodeficiency virus (HIV) presented with persistent oral candidosis in which non-albicans Candida strains were the predominant yeasts in most of the examinations performed over a period of 6 years. Oral treatment with fluconazole had no effect on clinical signs of oral candidosis. In 8 of a total of 11 specimens, Candida glabrata, Candida parapsilosis and Candida tropicalis were at least suspected as the causative pathogens of oral candidosis.

View Article and Find Full Text PDF

The introduction of HIV protease inhibitors was accompanied by reduction in HIV-associated opportunistic infections. Therefore, we performed a retrospective study of HIV-infected patients to evaluate the effects of therapy with an HIV protease inhibitor (PI) on oral candidosis. This was of special interest, because an important virulence factor of Candida albicans is the secreted aspartic protease (SAP), which is assigned to the same class of aspartic proteases as HIV protease.

View Article and Find Full Text PDF